VIR News and Press, Vir Biotechnology Inc. From 08/11/22

The Centers for Disease Control and Prevention (CDC) on Thursday revised recommendations for unvaccinated people easing the guidance on isolation following exposure to the virus. Per the latest advice, the CDC no longer recommends unvaccinated people to quarantine after exposure, ...

Vir Biotechnology ( NASDAQ: VIR ) has been hammered in after-hours trading and is down 15% after revealing it had a Q2 2022  non-cash charge of $397.4M for potential write-offs related to excess supply and manufacturing capacity of the COVID monoclonal antibody treatm...

Vir Biotechnology press release ( NASDAQ: VIR ): Q2 GAAP EPS of -$0.58 misses by $0.84 . More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing operations and liabili...

– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing operations and liabilities for up to five years – – Company provides update on COVID-19 dev...

It's really exciting to see triple-digit revenue growth. ShockWave Medical (NASDAQ: SWAV) and BioCryst Pharmaceuticals (NASDAQ: BCRX) are blowing the roof off right now, with 194% and 162% sales increases, respectively. Sometimes you see astronomical growth in a hea...

There are plenty of risks with biotech stocks. That's why it makes sense to invest in biotech companies that have plenty of likely growth but are also already profitable. Sure, you could take a flyer of a company that could go big with a breakthrough drug, but Vir Biotechnology (NASDA...

A 3-5 month prospect from here of Vir Biotechnology's share prices could reasonably range from a $26.63 low to a $36.17 high from its present price of $28.95, a +24.9% gain. The 24 prior positions like today’s expectations in 2.5 years of 601 market days averaged net gains at 2...

GSK ( NYSE: GSK ) Q2 sales grew on the back of growth in Specialty Medicines, including HIV, and shingles vaccine Shingrix, prompting the company to raise its FY22 sales outlook. Q2 Non-GAAP EPS rose +23% Y/Y (at AER) to £0.347, while total sales grew +19% Y/Y ...

SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2022, on Thursday, August 4, 2022. The corporate update and financial r...

A newly published study indicates that Evusheld, a monoclonal antibody therapy developed by AstraZeneca ( NASDAQ: AZN ) which is available in the U.S. for pre-exposure prophylaxis of COVID-19 might be less effective against new sub lineages of Omicron. The study was designed...